Medication info

New Mepirine Tablets (Glymepiride)

Prescription medicationApproval withdrawn
Ingredient · strength
Glimepiride›Strength being verified
Manufacturer / importer
Daehwa Pharmaceutical Co., Ltd.
Appearance
Green rectangular tablet
Packaging
100 tablets/bottle
Approval status
Approval withdrawn

MFDS item code 202002765 · Approved 2020.04.20

This product's status changed to Approval withdrawn on 2023.06.08. It may no longer be sold, so consult a doctor or pharmacist before taking it.

Summary

Main use
Improvement of glycemic control in type 2 diabetes mellitus
Who uses it
Adults
Adult dosage
Adjust the dose individually for each patient. Swallow without chewing with at least 1/2 glass of water. This medicine is administered orally once daily. It should be taken before breakfast or immediately before the first meal. It is very important not to skip a meal after taking this medicine. 1. Monotherapy 1) Initial dose and dose titration For patients who have not previously received medication, start treatment with 1 mg of glimepiride once daily. If needed, increase the dose by 1 mg at intervals of 1 ~ 2 weeks. In general, there is little additional benefit at doses above 4 mg, although some patients have achieved better metabolic control with an increase to 6 mg (or 8 mg). If treatment with 4 mg daily is unsuccessful, first consider switching to insulin therapy; otherwise, consider combination therapy with insulin or another oral antidiabetic medicine. 2) Subsequent dose adjustment As diabetes control improves during treatment, the need for this medicine may decrease. Therefore, dose reduction or discontinuation may be necessary to avoid hypoglycemia. Dose adjustment should also be considered in the event of weight loss, lifestyle changes, or other factors that may increase the risk of hypoglycemia or hyperglycemia. 3) Switching from another oral hypoglycemic agent to this medicine There is no exact dose equivalence between this medicine and other oral hypoglycemic agents. When switching from another oral hypoglycemic agent to this medicine, it is advisable to follow the method described under Initial dose. That is, start with 1 mg once daily and adjust the dose at 1 ~ 2-week intervals. The potency and duration of action of the previously administered medicine should be taken into consideration. 4) Dose adjustment during treatment Blood glucose and/or urine glucose levels should be measured regularly while taking this medicine; regular measurement of glycated hemoglobin (HbA1c) levels is also recommended. In general, hypoglycemia can be promptly controlled by immediately consuming sugar. Hypoglycemia may recur even after it has been successfully managed initially during treatment with a sulfonylurea. Therefore, patients should be monitored carefully. Severe hypoglycemia requires immediate medical treatment and follow-up, and hospitalization is sometimes necessary. 2. Combination therapy 1) Combination therapy with insulin Combination therapy with this medicine and insulin is used in patients with secondary failure and when fasting blood glucose (FBG) exceeds 150 mg/dL. Administer 8 mg of this medicine once daily with the first meal, and start insulin at a low dose, increasing it at approximately weekly intervals according to fasting blood glucose measurements. Once stabilized, monitor capillary blood glucose daily whenever possible. Insulin dose adjustment at regular intervals is necessary while measuring blood glucose and glycated hemoglobin. 2) Combination therapy with metformin If the patient does not respond adequately to the maximum dose of this medicine, adding metformin may be considered. Published clinical information is available on combination therapy of metformin with other sulfonylureas, such as glibenclamide, glipizide, chlorpropamide, and tolbutamide. When this medicine is used in combination with metformin, the desired blood glucose level can be achieved by adjusting the dose of each medicine. However, efforts should be made to identify the minimum effective dose of each medicine for glycemic control. There is a risk of hypoglycemia when this medicine is coadministered with metformin, and the risk may increase. Appropriate precautions should be taken.

Ingredients

Manufacturer
Daehwa Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in type 2 diabetes mellitus

  • Blood glucose control disorders in patients with type 2 diabetes
View approved original text

This medication is used to complement dietary and exercise therapy to improve blood glucose control in patients with type 2 diabetes. It can be used alone and may also be administered in combination with insulin when blood glucose control is insufficient with oral hypoglycemics. Additionally, it is used alongside metformin when sulfonylurea medications or metformin monotherapy are not effective, helping to control blood glucose more effectively in various ways and contributing to the prevention of diabetes complications.

Dosage and Administration

Adult dosage

Adjust the dose individually for each patient. Swallow without chewing with at least 1/2 glass of water. This medicine is administered orally once daily. It should be taken before breakfast or immediately before the first meal. It is very important not to skip a meal after taking this medicine. 1. Monotherapy 1) Initial dose and dose titration For patients who have not previously received medication, start treatment with 1 mg of glimepiride once daily. If needed, increase the dose by 1 mg at intervals of 1 ~ 2 weeks. In general, there is little additional benefit at doses above 4 mg, although some patients have achieved better metabolic control with an increase to 6 mg (or 8 mg). If treatment with 4 mg daily is unsuccessful, first consider switching to insulin therapy; otherwise, consider combination therapy with insulin or another oral antidiabetic medicine. 2) Subsequent dose adjustment As diabetes control improves during treatment, the need for this medicine may decrease. Therefore, dose reduction or discontinuation may be necessary to avoid hypoglycemia. Dose adjustment should also be considered in the event of weight loss, lifestyle changes, or other factors that may increase the risk of hypoglycemia or hyperglycemia. 3) Switching from another oral hypoglycemic agent to this medicine There is no exact dose equivalence between this medicine and other oral hypoglycemic agents. When switching from another oral hypoglycemic agent to this medicine, it is advisable to follow the method described under Initial dose. That is, start with 1 mg once daily and adjust the dose at 1 ~ 2-week intervals. The potency and duration of action of the previously administered medicine should be taken into consideration. 4) Dose adjustment during treatment Blood glucose and/or urine glucose levels should be measured regularly while taking this medicine; regular measurement of glycated hemoglobin (HbA1c) levels is also recommended. In general, hypoglycemia can be promptly controlled by immediately consuming sugar. Hypoglycemia may recur even after it has been successfully managed initially during treatment with a sulfonylurea. Therefore, patients should be monitored carefully. Severe hypoglycemia requires immediate medical treatment and follow-up, and hospitalization is sometimes necessary. 2. Combination therapy 1) Combination therapy with insulin Combination therapy with this medicine and insulin is used in patients with secondary failure and when fasting blood glucose (FBG) exceeds 150 mg/dL. Administer 8 mg of this medicine once daily with the first meal, and start insulin at a low dose, increasing it at approximately weekly intervals according to fasting blood glucose measurements. Once stabilized, monitor capillary blood glucose daily whenever possible. Insulin dose adjustment at regular intervals is necessary while measuring blood glucose and glycated hemoglobin. 2) Combination therapy with metformin If the patient does not respond adequately to the maximum dose of this medicine, adding metformin may be considered. Published clinical information is available on combination therapy of metformin with other sulfonylureas, such as glibenclamide, glipizide, chlorpropamide, and tolbutamide. When this medicine is used in combination with metformin, the desired blood glucose level can be achieved by adjusting the dose of each medicine. However, efforts should be made to identify the minimum effective dose of each medicine for glycemic control. There is a risk of hypoglycemia when this medicine is coadministered with metformin, and the risk may increase. Appropriate precautions should be taken.

Precautions

This medication should not be used in patients with insulin-dependent diabetes, diabetic ketoacidosis, or diabetic coma. Individuals allergic to this medication or its components should also avoid taking it. There is no experience using this medication in patients with severely impaired liver or kidney function, so switching to insulin therapy is recommended. In pregnant or potentially pregnant women, as well as breastfeeding women, it is safest not to use this medication. Patients with severe infections, those undergoing surgery, or those with significant trauma may require insulin therapy, so caution is necessary. When gastrointestinal disturbances such as diarrhea or vomiting occur, there is a risk of hypoglycemia due to inadequate absorption of food, so care is needed. This medication contains lactose, so individuals with lactose intolerance or related genetic disorders should not take it. During the initial stages of treatment, the risk of hypoglycemia is high, thus blood glucose levels should be monitored closely, especially in the elderly, those with poor nutritional status, or those with irregular eating habits. Imbalances in physical activity and food intake, changes in diet, and alcohol consumption may also increase the risk of hypoglycemia, hence caution is necessary. Patients with impaired liver or kidney function, other endocrine diseases, and those taking multiple medications should consult their doctor as they may have an increased risk of hypoglycemia. This medication contains Yellow No. 4 (tartrazine), so those allergic to this component should use it cautiously. Symptoms of hypoglycemia can include headache, severe hunger, nausea, fatigue, anxiety, confusion, drowsiness, and loss of consciousness. In severe cases, it may lead to seizures or coma. Transient visual disturbances or blurred vision may occur, and gastrointestinal symptoms such as nausea, vomiting, abdominal pain, and diarrhea may also appear. Serious side effects like liver dysfunction, blood abnormalities, and allergic reactions may occur rarely, so if any abnormal symptoms arise, medical personnel must be notified immediately. When taking this medication, regular meals, exercise, and weight management are important, and if hypoglycemia occurs, sugars should be consumed immediately to alleviate symptoms. Inform the doctor about all medications being taken, as concomitant use of other drugs may affect blood glucose control. In cases of pregnancy or breastfeeding, this medication may be harmful to the fetus or newborn, so it is advisable not to use it. For children under 18 years of age, safety and efficacy have not been established, so it is recommended not to use it. Elderly patients may experience delayed drug excretion due to reduced kidney function, thus requiring dosage adjustments. In the case of overdose, severe hypoglycemia may occur, requiring immediate medical attention and possibly emergency measures such as glucose injections.

Side effects

Hypoglycemia, headache, severe hunger, nausea, vomiting, fatigue, sleep, sleep disturbances, anxiety, aggression, decreased concentration, decreased agility or motivation, depression, confusion, speech abnormalities, aphasia, visual impairment, tremor, incomplete paralysis, sensory disturbance, dizziness, weakness, loss of self-control, transient mental confusion, brain convulsions, drowsiness, loss of consciousness, coma, shallow breathing, bradycardia, sweating, cold and clammy skin, tachycardia, hypertension, palpitations, angina, venous dysrhythmia, blurred vision, fullness or pressure in the upper abdomen, abdominal pain, diarrhea, increased hepatic enzymes, abnormal liver function, bile secretion disorders, jaundice, hepatitis, thrombocytopenia, leukopenia, hemolytic anemia, erythrocytopenia, agranulocytosis, pancytopenia, itching, urticaria, rash, dyspnea, hypotension, shock, anaphylaxis, angioedema, Stevens-Johnson syndrome, allergic vasculitis, photosensitivity reactions of the skin, decreased serum sodium concentration, taste disturbances, hair loss, weight gain, dizziness, abnormal liver function, abdominal pain, arthralgia, dyspepsia, facial swelling, erectile dysfunction, flushing of the face, gastritis

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly sealed container to avoid exposure to air and moisture. It is safest to store it at room temperature, between 1°C and 30°C.

Appearance and packaging

Appearance

Green rectangular tablet

Package unit

100 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.